An aging population and behavioral lifestyle changes are supporting the increasing incidence of metabolic diseases across Europe. This Frost & Sullivan report examines ongoing developments across this vast and dynamic industry. To provide a thorough overview of the European market, the report covers four disparate segments: diabetes, including both insulin and oral hypoglyceamic agents; obesity; growth hormones; and erythropoietin. The report provides information on market size and growth, market share, revenue forecasts, pricing strategy and trend analysis, the competitive structure, and more.
